LEXICON PHARMACEUTICALS, INC.(LXRX)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

LEXICON PHARMACEUTICALS, INC. (LXRX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LXRX at 33.7/100 on a 32-signal composite quality model, placing it at rank #2,382 of 2,961 stocks — the bottom half of the AI-ranked universe. LXRX scores in the top quartile across revenue growth (99.3), institutional flow (81.4). Areas of concern include free cash flow (5.3) and profitability (6.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 7.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), LEXICON PHARMACEUTICALS, INC. reports quarterly revenue of $692.0K, net income of $-31.8M. Top institutional holders of LXRX by reported 13-F value include Artal Group S.A., FMR, Siren, L.L.C., based on the most recent SEC filings. LXRX trades on the Nasdaq exchange and files with the SEC under CIK 1062822. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LXRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for LEXICON PHARMACEUTICALS, INC. directly from SEC EDGAR.